Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics : Reports that its Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19

06/16/2021 | 01:10am EDT
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19

Geneva, Switzerland, June 16, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ('Relief'), a biopharmaceutical company with its lead compound RLF-100™ (aviptadil) in advanced clinical development to treat COVID-19-induced respiratory disorders, reported today that its collaboration partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP) ('NRx') has announced additional results from the aviptadil U.S. Expanded Access Protocol (EAP). The EAP included 240 patients in the intensive care unit (ICU) with critical COVID-19 respiratory failure requiring either invasive or non-invasive mechanical ventilation, or high flow rate oxygen by nasal cannula, and not eligible for the recently completed phase 2b/3 clinical trial with IV aviptadil. According to NRx's press release, these EAP data are being submitted by NRx to the U.S. Food and Drug Administration (FDA) as 'real world' evidence in support of the findings from the phase 2b/3 trial. The related NRx press release can be accessed through the following link.

###

ABOUT RELIEF


Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical development in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com.

Follow us on LinkedIn.

Disclaimer

Relief Therapeutics Holding AG published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 05:09:03 UTC.


ę Publicnow 2021
All news about RELIEF THERAPEUTICS HOLDING AG
07/26RELIEF THERAPEUTICS : to Raise $16.3 Million to Expand Drug Pipeline
MT
07/26RELIEF THERAPEUTICS : Announces CHF 15 Million Private Placement
EQ
07/23RELIEF THERAPEUTICS : US Partner NRx Validates Commercial Formulation of Aviptad..
MT
07/23EQS-NEWS : Relief Reports that its U.S. Collaboration Partner has Announced Succ..
DJ
07/22EQS-NEWS : Relief Announces Issuance of Shares from Authorized Capital as Approv..
DJ
07/20RELIEF THERAPEUTICS : Says Aviptadil Prevents Cytokine Storms in COVID-19 Patien..
MT
07/20EQS-NEWS : Relief Reports that its U.S. Collaboration Partner has Presented Evid..
DJ
07/13RELIEF THERAPEUTICS : Partner NRx Starts Mid-Stage Study Of Inhaled COVID-19 Dru..
MT
07/13EQS-NEWS : Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceu..
DJ
06/29RELIEF THERAPEUTICS : to Buy Swiss-Based APR Applied Pharma Research
MT
More news
Financials
Sales 2021 260 M 284 M 284 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 856 M 934 M 934 M
Capi. / Sales 2021 3,29x
Capi. / Sales 2022 1,70x
Nbr of Employees 10
Free-Float 45,3%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Last Close Price 0,25 CHF
Average target price 0,93 CHF
Spread / Average Target 270%
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Gilles Della Corte Chief Medical Officer
Taneli Jouhikainen Chief Operating Officer
Jeremy Meinen Vice President-Finance & Administration
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-6.69%767
MODERNA, INC.221.50%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.38.02%47 022
CELLTRION, INC.-26.46%32 170
SEAGEN INC.-18.34%28 525